Xiansheng Pharmaceutical (02096) spent nearly HK$15 million on the long-term repurchase principle to inject confidence into the market

The Zhitong Finance App learned that on September 10, Xiansheng Pharmaceutical (02096) continued to repurchase shares. Following yesterday's repurchase of 929,000 shares, the company once again spent about HK$14.2453 million to repurchase 1.265,000 shares. The repurchase price range was between HK$11.17 and HK$11.38. The company's continuous action shows the importance it attaches to shareholders' rights and the company's confidence in adhering to long-term development.

In the first half of 2026, the company handed over an impressive report card: total revenue of 4.58 billion yuan, up 27.8% year on year; adjusted net profit of 960 million yuan, up 48.7% year on year; innovative drug revenue share climbed to 85%, and product and R&D capabilities were recognized.

At the same time, the company's subsidiary Xiansheng Zaiming has signed an exclusive licensing agreement with Roche (Roche) to reach global development and commercialization cooperation on the CD79a/CD19/CD3 tri-specific antibody Sim0660, with a total transaction payment of up to US$1.53 billion, including a down payment of US$75 million. Based on future net sales, Xiansheng may also be entitled to charge tiered royalties of up to double digits.